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IGF = insulin-like growth factor; IRS = insulin receptor substrate; mtDNA = mitochondrial DNA; nDNA = nuclear DNA; PI3 = phosphoinositol-3;
TNF = tumor necrosis factor.
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Introduction
Insulin-like growth factor (IGF)-1 is a well characterized
growth factor for a variety of cells and plays a role in the
regulation of myocardial structure and function. There is
evidence that IGF-1 improves cardiac performance and
muscle survival in heart subjected to ischemia/reperfusion
[1,2]. Therefore, elucidating the IGF-1 signaling pathways,
especially in relation to cell survival, may help to promote the
potential use of IGF-1 in the treatment of heart disease.
Using an ex vivo murine model, Davani and coworkers [1], in
this issue of Critical Care, demonstrate that IGF-1 confers
cardiac protection from reperfusion injury via mitochondria-
dependent mechanisms. Because of its vital role in
myocardial energy production, the quantity of functional
mitochondria is essential to myocardial activity and health.
Davani and coworkers propose that the ratio of mitochondrial
DNA (mtDNA) to nuclear DNA (nDNA), which is increased
during ischemia and reduced with reperfusion, is a very
sensitive marker of cardiac injury. They then use the
mtDNA:nDNA ratio to demonstrate that IGF-1, which
prevents the reduction in mtDNA:nDNA ratio that occurs
during reperfusion, confers myocardial cytoprotection. The
mtDNA:nDNA ratio emphasizes the importance of
mitochondria-related mechanisms in reperfusion injury, and it
also provides a novel reference for evaluating cardiac injury.
Insulin-like growth factor-1 mediated cell
survival in myocardial tissue
Insulin-like growth factor-1 signaling pathways in
myocardial tissue
Two distinct forms of cell death, namely necrosis and
apoptosis, are involved in the survival effect of IGF-1 in the
cardiovascular system. IGF-1 not only inhibits necrosis via
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Abstract
Insulin-like growth factor (IGF)-1 is a well characterized growth factor that plays a role in the regulation
of myocardial structure and function. Using an ex vivo murine model, Davani and coworkers, in this
issue of Critical Care, demonstrate that IGF-1 confers cardiac protection against ischemia via
mitochondria-dependent mechanisms. Those investigators used the ratio of mitochondrial to nuclear
DNA to demonstrate that IGF-1, which prevents reduction in this ratio during reperfusion, provides
cytoprotection. This commentary also reviews mechanisms of IGF-1 function and provides a graphic
representation of IGF-1 signaling mechanisms in potential crosstalk relations with mediators of
inflammation in the heart (specifically tumor necrosis factor-α).
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preservation of mitochondrial function, specifically by
inhibiting membrane permeability and cytochrome C release
in mitochondria, but also it reduces apoptosis through the
inhibition of death signals generated by mitochondria [3].
IGF-1 survival signals are mediated by binding to its receptor,
the type 1 IGF receptor. This receptor is a heterotetramer
containing cytosolic substrates (insulin receptor substrate
[IRS], Shc, and Gab-1), which serve as docking proteins for
downstream events. It has been demonstrated that IGF-1
mediated survival correlates with the activation of the protein
kinase Akt, and this pathway was disrupted by applying
wortmannin, a specific inhibitor of phosphoinositol-3 (PI3)-
kinase, in different models of cardiac ischemia [4,5].
Moreover, the antiapoptotic effects of IGF-1 are abolished if
Akt activation is suppressed during ischemia/reperfusion
injury in transgenic mouse hearts that over-express IGF-1 [6].
Recent studies revealed that IGF-1 induced myocardial
protection from ischemia/reperfusion injury is associated with
attenuated Bax induction and caspase 3 activation [3,7].
There is also evidence that P70 S6 kinase is involved in the
survival signal of IGF-1 in H9c2 cells, and a PI3-
kinase→Akt→P70 S6 kinase pathway exists in
cardiomyocytes [8].
However, IGF-1 induced myocardial protection cannot be
explained by the PI3-kinase/Akt pathway alone. In addition to
inhibition of Bax expression, the protective effect of IGF-1 is
associated with the inhibition of C-jun N-terminal protein
kinase activation [9]. Moreover, Yamashita and coworkers [6]
showed that inhibition of p38 mitogen-activated protein
kinase activation was accompanied by suppression of Akt
activation during ischemia/reperfusion in the IGF-1
transgenic heart.
Therefore, IGF-1 receptor binding serves as an extracellular
signal to stimulate its intracellular substrate IRS, which leads
to activation of PI3-kinase. The products of the PI3-kinase
reaction then activate Akt. Activated Akt kinase plays a
crucial role in antiapoptosis by modulating different signal
downstream events (Fig.1).
Insulin-like growth factor-1 and tumor necrosis factor
Tumor necrosis factor (TNF)-α is a proinflammatory cytokine
that has been implicated in the pathogenesis of
cardiovascular disease. Myocardial TNF-α is an autocrine
contributor to myocardial contractile dysfunction and
cardiomyocyte death in ischemia/reperfusion injury, sepsis,
chronic heart failure, viral myocarditis, and cardiac allograft
rejection [10].
Accumulating evidence shows that crosstalk of TNF-α and
IGF-1 signaling pathways may modulate biologic functions in
cardiovascular tissue. Patients with chronic heart failure
exhibit an inverse relationship between IGF-1 and TNF levels
[11]. Drugs that increase the concentration of TNF-α
decrease IGF-1 concentration in the rat heart [12]. It has
been demonstrated that TNF-α suppresses IGF-1 mRNA
expression and upregulates IGF-binding protein 3 [13].
Moreover, TNF-α attenuation of IGF-1 may be involved in
phosphorylation of the c-Jun pathway [14]. On the other
hand, it has been suggested that the cytoprotection
associated with IGF-1 is correlated with downregulation of
nuclear factor-κB activation induced by TNF-α [15].
IGF-1 is important for the growth and survival of
cardiovascular tissue. However, long-term IGF-1 treatment
downregulates the expression of Gab1 associated with
MEKK3, which enhances TNF-induced c-Jun and nuclear
factor-κB activation, as well as adhesion molecule expression
in endothelial cells [9]. Long-term IGF-1 treatment thus leads
to hypersensitivity to TNF-mediated signaling events.
Effects of insulin-like growth factor-1 on
myocardial function
IGF-1 is not only an important survival factor for the heart, but
it also plays a role in improving cardiac function. IGF-1 has
been shown to improve perfusion pressure and left
ventricular compliance in ischemia/reperfusion by decreasing
interstitial edema, preserving the myocardial tissue lattice,
and protecting mitochondrial integrity [1]. IGF-1 mediated
protection of cardiac contractility may be involved in the PI3
kinase pathway and in activation of protein kinase C [16].
IGF-1 induces increases in intracellular calcium [17] and
myofilament calcium sensitivity, both of which improve
cardiac contractility [16].
Figure 1
Model of insulin-like growth factor (IGF)-1 mediated signal
transduction pathways to regulate cell survival in myocardial tissue.
IRS, insulin receptor substrate; JNK, C-jun N-terminal protein kinase;
MEKK, mitogen-activated protein kinase kinase kinase; NFκB, nuclear
factor-κB; PI3, phosphoinositol-3; PIP, phosphoinositol-4-phosphate;
TNF, tumor necrosis factor.
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Conclusion
IGF-1 is an important growth factor for the survival and
function of the heart. Accordingly, much focus has been
given to IGF-1 as a potential therapeutic agent. Indeed, it has
been shown that IGF-1 has a cytoprotective effect in different
models of cardiac ischemic injury. However, the role of IGF-1
in cardiovascular disease is still not clear. Recent evidence
suggests that long-term exposure to IGF-1 may actually be
detrimental to the heart. It is clear that further investigation of
the IGF-1 signaling network is needed before its clinical
application can be declared.
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